ProShares Ultra NASDAQ Biotechnology
24 hedge funds and large institutions have $6.47M invested in ProShares Ultra NASDAQ Biotechnology in 2024 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more ownership
Funds ownership: →
21% less call options, than puts
Call options by funds: $764K | Put options by funds: $972K
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
Holders
24
Holding in Top 10
–
Calls
$764K
Puts
$972K
Top Buyers
| 1 | +$954K | |
| 2 | +$731K | |
| 3 | +$702K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$532K |
| 5 |
Jane Street
New York
|
+$262K |
Top Sellers
| 1 | -$797K | |
| 2 | -$288K | |
| 3 | -$144K | |
| 4 |
CIC
Chase Investment Counsel
Charlottesville,
Virginia
|
-$90K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$24.5K |